Chlorhexidine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Chlorhexidine: From Topical Antisepsis to Chronic Ethmoidal Sinusitis
One-Sentence Summary
Chlorhexidine is a broad-spectrum topical antiseptic conventionally used for skin, oral and wound disinfection. The TxGNN model predicts it may be effective for Chronic Ethmoidal Sinusitis, but this direction is currently supported by only 1 publication and no registered clinical trials, so the evidence base is very early-stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this evidence pack — no ARTG licence text on file. Chlorhexidine is generally used as a topical antiseptic/disinfectant (skin, oral, wound) |
| Predicted New Indication | Chronic Ethmoidal Sinusitis |
| TxGNN Prediction Score | 95.46% |
| Evidence Level | L4 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on general pharmacological knowledge, chlorhexidine is a bis-biguanide antiseptic that disrupts bacterial and fungal cell membranes, and is widely used to reduce microbial load on skin, oral and wound surfaces. Mechanistically, this same antimicrobial action could plausibly extend to reducing bacterial burden on nasal and paranasal sinus mucosa, including the ethmoidal sinuses, in cases where chronic sinusitis has a bacterial component.
The repurposing rationale in the evidence pack notes that this is analogous to the general sinusitis mechanism: local antimicrobial disinfection may lower the bacterial load associated with chronic ethmoidal sinusitis. However, this is supported by only a single, small, indirectly-related cohort study, with no controlled trials — so the mechanistic plausibility is reasonable but the clinical evidence behind it is currently weak.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16008068 | 2005 | Cohort | Rhinology | Investigated whether nasal cavity disinfection influences bacteriology results in the bulla ethmoidalis of patients with chronic sinusitis — an indirect, hypothesis-generating finding rather than a treatment trial |
Australia Market Information
Chlorhexidine is not currently marketed in Australia under this evidence pack — 0 ARTG entries are on file, and market status is recorded as “Not marketed.”
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. This evidence pack has no on-file key warnings, contraindications, or drug interaction data for chlorhexidine, and TFDA/TGA label warnings are flagged as a Blocking data gap that must be resolved before any safety assessment can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication is currently backed by only a single small, indirectly-related cohort study (L4 evidence) with no clinical trials, and a Blocking data gap exists for basic safety information (TFDA warnings/contraindications). Without safety data, the candidate cannot progress past an initial safety screen, so it should be held pending further evidence rather than advanced.
To proceed, the following is needed:
- TFDA/TGA-approved safety information (warnings, contraindications) — currently a blocking gap
- Detailed mechanism of action (MOA) data
- Controlled clinical trials, or at minimum larger observational studies, specifically evaluating chlorhexidine (via a nasal/sinus route) in chronic ethmoidal sinusitis
- Route compatibility assessment — no available or required administration routes have been confirmed for this indication
- Clarification of Australian market/registration pathway, since chlorhexidine currently has no ARTG entries
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.